Related Experiment Videos
Effect of recombinant human erythropoietin after allogenic bone marrow transplantation
1Interdisciplinary Unit for Bone Marrow Transplantation, Medical School, Hannover, Germany.
Annals of Hematology
|October 1, 1993
Abstract:
The hematologic effects of recombinant human erythropoietin after allogeneic bone marrow transplantation (BMT) were studied. Nineteen patients received 150 U/kg/day of C127 mouse-cell-derived recombinant human erythropoietin (rHu EPO) as a daily continuous intravenous infusion until hematocrit exceeded 35%. These data were compared with a treatment-matched historical control group of 43 patients. RHu EPO-treated patients recovered erythropoiesis more rapidly and became independent from erythrocyte transfusions after a median of 17 days, which was 7 days earlier than the control patients.